Introduction
Examples of stratified medicine, in which a companion diagnostic test, applying genetic or biomarker information, is used to target treatments to subgroups of patients, are now emerging into clinical practice. A number of synonymous terms and concepts, such as personalised medicine, pharmacogenetics and pharmacogenomics, are used in the literature [1•, 2] . To date, however, there are few examples of personalised medicine. Many of the existing clinical applications involve a stratified approach to medicine, in which a pretreatment aim is to identify those patients who are most likely to effectively and safely respond. This article focuses on the potential for stratified medicine in rheumatoid arthritis, from an economic perspective.
Rheumatoid arthritis (RA) is a common autoimmune condition affecting up to 1 % of the population and is characterised by inflammation of synovial joints, which can lead to irreversible joint damage and disability. National Audit Office figures indicate that 45 % of RA patients are of working age and within 1 year of diagnosis, around 30 % of patients are unemployed because of their disease (www.nao. org.uk). It is estimated that RA costs the NHS in England approximately £560 million annually in direct healthcare costs and up to £4.8 billion per year in work-related disability. The biggest modifier of prognosis is treatment and the introduction of early, effective therapy has consistently been shown to improve long-term outcomes, including the degree of joint damage, disability and unemployment [3] [4] [5] .
The treatment of RA is informed through Europeanproduced clinical guidelines [6] . In England, the National Institute for Health and Care Excellence (NICE) offers treatment guidelines for RA [7, 8] . However, even with the availability of such guidelines, clinicians still have a number of explicit choices to make when defining a treatment pathway for an individual patient with RA. Methotrexate, a diseasemodifying anti-rheumatic drug (DMARD), is recommended by NICE as the first-line treatment for RA and has very modest drug costs (£75 per year, per patient); however, only 55 % of patients remain on this relatively inexpensive therapy 2 years post diagnosis. Those patients who fail to respond to methotrexate and at least one other DMARD become eligible for the more expensive biologic treatments (costing approximately £8-10,000 per patient, per year). These biologic therapies include a number of treatment options such as TNFpathway blocking drugs (anti-TNFs); the CTLA4 analogue, abatacept; an IL6 pathway-blocking drug, tocilizumab and the B cell-depleting therapy, rituximab. There is a significant nonresponse rate to all of these treatments. For example, around one quarter of patients fail to respond to anti-TNF biological drugs. The inability to predict which patients will, or will not, respond to a particular therapy before a treatment has started results in a major unmet medical need.
Stratified medicine in RA potentially allows for the identification of safe and effective response predictors to inform the development of companion diagnostic tests to guide treatment selection. Using such a companion diagnostic test would facilitate the allocation of patients to strata, defined by the therapy they are most likely to respond to, early in the disease process. RA provides an ideal setting in which to introduce a stratified approach to medicine. To prevent irreversible joint damage, a stratified approach would promote early identification and fast-tracking of the strata of patients destined to require biological therapy. Getting the treatment right the first time is the key to improve short-and long-term health and non-health outcomes for patients with RA [9] . Furthermore, achieving a safe and good response early in the treatment pathway may result in a cost-effective use of healthcare resources and reduce the economic burden of RA to society. The earlier a patient with RA is treated with the most appropriate therapy, the more likely they are to experience a sustained improvement in health-related quality of life and the less likely the health resources forgone will be used to fund an ineffective treatment.
There are a number of potential options for stratified medicine in the context of RA [10, 11•] . Figure 1 provides a simplified overview of the diagnostic and treatment pathway for RA and shows some potential applications of a stratified approach to predicting, diagnosing and treating RA [12, 13] . The implementation of a stratified approach to diagnose and manage RA, as illustrated in Fig. 1 , raises additional challenges and research questions that require a robust evidence base. For instance, the point at which the predictor biomarkers should be tested will be biomarker dependant. Genetic biomarkers for treatment response are not only considered to be ideal as they are stable and reliably tested, but also raise issues about data storage and confidentiality. In contrast, other predictive markers such as anti-drug antibodies can only be tested once a patient has started therapy, and the test results need to be generated close to when the sample is taken. A key unknown is if, and how, the result of the biomarker test will influence the prescribing and treating behaviour of a physician. Clearly, patients are key stakeholders in the use of stratified medicine. However, the influence of an accompanying diagnostic test to determine the response to treatment of the patient, and their subsequent behaviour, is unknown.
The above issues highlight the need for a robust clinical and economic evidence base, before stratified medicine for RA can be introduced into routine practice. Methods of economic evaluation, such as cost-effectiveness analysis, can generate information on the relative costs and benefits of using a stratified approach to medicine, compared to the conventional non-stratified approach. Despite the potential advantages of conducting a formal economic evaluation, many countries do not use the results of economic analyses as a tool to inform healthcare decision-making in the context of stratified medicine [14] . Similarly, stated preference methods (such as discrete choice experiments) can be used to identify which characteristics of a proposed new technology drive preferences and can potentially be used to inform health service developments underpinned by the views of patients, clinicians and the general public [15] .
There are 12 published systematic reviews of the current economic evidence base, to support the use of approaches to personalised or stratified medicine, in terms of costeffectiveness [16-22, 23•, 24-27] . De Bekker-Grob et al. [15] have also produced a review of all published discrete choice experiments in healthcare. None of these reviews, however, have explicitly focussed on the implications of stratified medicine in the context of the emerging paradigm of stratified medicine in RA.
The aim of this study is to understand the current economic evidence base for stratified medicine in RA, by evaluating the following: (i) published economic evaluations of stratified approaches to treating RA, and the use of subgroups in economic analyses, and (ii) stated preference studies that aim to elicit preferences for stratified approaches to treatments for RA.
Methods
Two systematic reviews were conducted to identify the economic evidence for stratified approaches in RA, by finding (i) all published economic evaluations of treatments for RA that focussed on a stratified approach, or had included a subgroup analysis within the economic evaluation, and (ii) all published studies that had used a stated preference experiment, including discrete choice experiments (DCE), conjoint analysis (CA), adaptive conjoint analysis (ACA) or best-worst scaling (BWS) methods, to elicit preferences for treatment options in RA. The methods used to identify these two sets of literature are described below.
Identifying Economic Evaluations of Stratified Approaches in RA
We identified all economic evaluations of treatments for RA, which were published between January 1990 and April 2014. This included trial-based, observational-based and modelbased economic evaluations published in peer-reviewed journals. From this complete list, economic evaluations were identified which had either (i) evaluated a stratified medicine that used an explicit targeted approach to defining the study population or (ii) included a subgroup analysis as part of the economic evaluation. An explicit targeted approach was defined as when a clinical decision is made for a subset of the patient population according to the outcome of a diagnostic test. A subgroup analysis was defined as the situation in which cost-effectiveness results are presented for subgroups of the larger patient population. The subgroup analyses could have been either explicitly defined as a subgroup analysis in the methodology or implicitly treated as such within a deterministic sensitivity analysis of a single model parameter value to generate the subgroups.
Supplementary Appendix 1 summarises the search strategies used. The search strategy was run in April 2014 in the following electronic databases: Ovid MEDLINE (full version, in-process and other non-indexed citations' version and daily update version), Ovid Embase, Web of Science and the NHS Economic Evaluations Database (accessed via the Centre for Reviews and Dissemination databases).
Identifying Stated Preference Studies of Stratified Approaches in RA
Stated preference studies (published between 1990 and April 2014) relevant to treatments for RA were identified by using a previously published systematic review strategy (see Supplementary Appendix 2) to identify DCEs in healthcare [28] , in combination with condition-specific terms for RA. The following databases were searched on 27 May 2014: Web of Science, MEDLINE, Embase, PsycINFO and EconLit.
The Study Inclusion Process
Two reviewers independently screened all retrieved titles and abstracts to identify the studies eligible for inclusion in the systematic reviews. Conference abstracts, opinion/review/ protocols and non-English articles were excluded. Following the initial screen of abstracts, full copies of papers were obtained and read in full, for the final review. Economic evaluations (as defined by Drummond et al. [29] ) and stated preference studies relevant to treatments in RA were included if they had met the inclusion criteria that are detailed in Supplementary Appendix 3. Within the total sample of identified economic evaluations of treatments for RA, those which involved a targeted approach or a subgroup analysis were identified at the data extraction stage by one reviewer (SG).
Data Collection and Extraction
Data were extracted from the identified studies by two reviewers (SG: economic evaluations; MH: stated preference studies) using a structured data collection form relevant to each study design (economic evaluation or stated or preference study). Results from both reviews were tabulated and then summarised in a narrative synthesis.
Results
This section summarises the main results from the systematic reviews of (i) economic evaluations of explicit targeted approaches to treatment for RA, and those which had included a subgroup analysis, and (ii) stated preference studies of stratified approaches to RA treatments.
Economic Evaluations of Stratified Approaches in RA
The systematic search strategy identified a total of 128 economic evaluations of treatments for RA, which were published between January 1990 and April 2014. Supplementary Appendix 4 summarises the study identification and inclusion process.
Half of the 128 economic evaluations had focussed exclusively on biologic treatments for RA, whilst approximately 30 % of the economic evaluations had solely evaluated either DMARD (n=15) or NSAID (n=24) therapy. Thirty eight economic evaluations included some form of subgroup analysis, and ten involved evaluating an explicit targeted approach to treatment. Of the 38 economic evaluations with a subgroup analysis, nine of the analyses had presented results exclusively by age and/or gender, whilst 25 evaluations had considered age and/or gender as potential subgroups amongst other patient characteristics. Such patient characteristics, by which cost-effectiveness results were reported, were used to create subgroups relating to, for example, smoking status, baseline disease severity, history of previous adverse events and the use of drug treatments additional to that being evaluated. Four of the studies with subgroup analyses were based on observational data [30] [31] [32] [33] , and one study combined an RCT with a model-based analysis [34] . The summaries of all 38 studies are available in Supplementary Appendix 5. Table 1 provides an overview of the ten studies that had included an explicit targeted approach to treatment for RA. Supplementary Appendix 5 provides a more detailed summary of these ten studies. Nine of the studies were model-based economic evaluations. The general focus of the targeted approach was to use a companion diagnostic to predict the risk of specific adverse drug-related events (n=7 studies [35, 36, 38, [40] [41] [42] 44] ). Two studies evaluated the optimisation of treatment(s) according to the result of a diagnostic test [39, 43] . One study evaluated the use of a diagnostic test to identify and treat RA patients from a wider set of patients with undifferentiated arthritis [37] . In general, the results from these evaluations suggested that the stratified approach was a cost-effective use of resources; however, there were key uncertainties in the data used to populate the models. The single trial-based study that we identified here as considering an explicit targeted approach to treatment in RA also reported extensive variation around the estimated mean costs and quality-adjusted life years [44] .
Stated Preference Studies of Stratified Approaches in RA
Eight studies using stated preference methods in the context of RA were identified. Supplementary Appendix 6 shows the study inclusion process. Table 2 summarises the identified stated preference studies. The eight papers included three DCEs [45, 50, 51] , four ACA [46] [47] [48] [49] , and one used a contingent ranking exercise [52] . Seven papers elicited preferences from people with RA and one from physicians; all studies involved eliciting preferences for drug treatment options, either non-biologic DMARDs or biologic DMARDs. None of the identified studies set out to explicitly assess preferences for stratified medicine, but one study included attributes which helped to identify physician preferences for treating people with RA according to clinical features [49] . Physicians who were asked whether they would escalate care (initiating a new biologic treatment) on the basis of six attributes, which represented characteristics that could be observed in a clinical examination, were found to place the greatest importance on disease activity, age and joint damage.
Three studies used subgroup analyses to provide evidence of potential differences in the treatment preferences of different groups of individuals, which could be informative for stratified medicine. Fraenkel [48] discussed findings of greater risk aversion towards drug toxicity in older patients being a factor to consider, when selecting treatments for people with RA. Similarly, two papers reporting the same ACA find differences according to ethnicity, between groups of people with RA, for the risk/benefit profile of treatments which they receive, which may explain the differential use of certain drugs [46, 47] . African-American people placed the most importance on the risk of cancer, whilst white patients placed the most importance on the likelihood of remission [46] . There was also a difference in preferences for aggressive treatment, with 50 % of white patients (compared with 16 % Perspectives are as reported within each economic evaluation
CUA cost-utility analysis, CEA cost-effectivenessanalysis, PSA probabilistic sensitivity analysis of African-American respondents) wanting this approach to managing their RA [47] .
Discussion
This review has identified an emerging economic evidence base to support the use of stratified medicine in patients with RA. To date, however, there is limited evidence to understand some key aspects of the potential added value of proposed applications of stratified medicine in RA, including the correct approach to the sequencing of available biologic drugs to achieve a rapid, effective and safe response early in the care pathway. A related issue that is not yet supported by an economic evidence base is the potential use of panels of genetic and/or biomarker tests as part of the diagnostic care pathway to inform the subsequent sequencing of treatment. This panel-based approach to testing introduces the need to understand when in the diagnostic pathway to test patients, how to report test results and how to store the test results for subsequent use in a timely and effective manner. These issues, when combined, raise significant capacity issues for constrained healthcare systems. The current costeffectiveness evidence base is dominated by Markov model-based evaluations, which are useful in the context of identifying incremental costs and benefits of new technologies at the population level. Alternative modelbased approaches, such as discrete event simulation, would allow an assessment of the impact of the capacity of the health service and workforce, to deliver timely and effective stratified approaches to medicine for patients with RA [53, 54] . Alternative analytic approaches are also needed to understand the presence and impact of heterogeneity in the context of stratified approaches. A practical challenge for all economic evaluations of stratified medicine in RA will be, however, the gaps in the clinical evidence base needed to populate robust model-based evaluations, which could be addressed by using validated expert elicitation methods (for example, see Soares et al. [55] ). Methods of economic evaluation, in general, and costeffectiveness and cost-utility analysis, specifically, are necessary but not sufficient on their own to provide decisionmakers allocating scarce healthcare resources with information to support the introduction of stratified medicine in RA. There are two key stakeholders whose preferences and views will drive the eventual success of using stratified medicine in RA: clinicians and patients. Thompson et al. [44] suggested that clinicians may not always use the results from a thiopurine s-methyltransferase (TMPT) genetic test to inform subsequent prescribing behaviour, which undermines the potential value of the test to improve patient outcomes. Companion diagnostic tests, such as TMPT, offer a potential added value in terms of risk reduction by being able to identify patients at risk of adverse events before they occur. However, for this potential risk reduction to be observed in practice, clinicians (and patients) must perceive that such an added value exists and trust the evidence base supporting the use of the test. Stated preference studies could be used to elicit clinicians', and patients', perceptions of the added value of using companion diagnostics to identify and reduce the risk associated with taking medicines for RA. Similarly, preferences for the potential value of using a stratified approach to improve short-and long-term outcomes, and response rates, to medicines for RA could also be quantified using stated preference studies. A logical progression from this idea is that a patient's perceptions of the value of a stratified approach could affect their adherence to medicines, when guided by a stratified approach. There was some evidence identified in this review that particular groups of patients may have different preferences for the balance between risk and benefit of a treatment, and therefore, in theory, the additional information from a stratified approach could provide reassurance and affect adherence of these groups to treatment [46] [47] [48] . To date, there is no evidence to support the hypothesis that stratified medicine does improve patient adherence. These areas provide ample scope for future research, to generate a robust economic evidence base to support the introduction of stratified medicine in RA.
Conclusion
This review has identified some key gaps in the economic evidence base needed to support the introduction of stratified medicine in RA into healthcare systems. Stratified approaches to treating a patient with RA may be costeffective, as demonstrated by the few economic evaluations already in existence. However, in the absence of robust clinical evidence, there is likely to be much uncertainty in how a proposed stratified approach will impact future patient outcomes and costs when used in routine practice. Preferences towards a stratified approach may also affect the viability of its introduction in practice. The value of a diagnostic test to stratify treatment is lost if a physician fails to follow the action indicated by the test result. Conversely, adherence to a given treatment may improve, if a patient's treatment is stratified according to their benefit/risk preference. Appropriately defined research questions using robust methods of economic evaluation and/or stated preference studies could meet the need for further evidence.
